Improved Total-Body Irradiation Survival by Delivery of Two Radiation Mitigators that Target Distinct Cell Death...

Area of Science:

• Radiation biology
• Pharmacology
• Toxicology

Background:

• Total-body irradiation (TBI) causes acute lethality through multi-organ damage, primarily bone marrow and intestine.
• JP4-039 (anti-apoptotic) and necrostatin-1 (anti-necroptotic) are effective radiation mitigators when administered post-TBI.
• Necrostatin-1's efficacy is optimal at 48 hours post-TBI, coinciding with elevated necroptosis-inducing cytokines and RIP3 phosphorylation.

Purpose of the Study:

• To investigate if JP4-039 administration influences the optimal timing for necrostatin-1 delivery after TBI.
• To determine if sequential administration of JP4-039 and necrostatin-1 enhances survival compared to single-drug treatment.

Main Methods:

• Mice (C57BL/6NTac female) received 9.25 Gy TBI (LD50/30).
• Daily plasma, intestine, and bone marrow protein levels (33 proteins) were measured for 7 days post-TBI.
• JP4-039 was administered at 24 hours post-TBI, followed by necrostatin-1 at 72 hours post-TBI, based on observed RIP3 kinase elevation delays.

Main Results:

• TBI induced distinct protein responses in plasma versus tissue samples.
• JP4-039 administration delayed the optimal necrostatin-1 delivery window.
• Sequential administration of JP4-039 and necrostatin-1 significantly increased survival rates compared to single-drug treatments.

Conclusions:

• The optimal timing for necrostatin-1 administration can be influenced by prior treatment with JP4-039.
• Sequential administration of these radiation mitigators represents a promising strategy for improving survival after TBI.
• Understanding TBI-induced molecular dynamics is crucial for optimizing radioprotective drug delivery.